Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjunctive immunotherapy of tuberculosis

Z Toossi1

  • 1Case Western Reserve University, Cleveland, OH 44106, USA. zxt2@cwrupoedu

Cytokines, Cellular & Molecular Therapy
|July 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD4 T-cell cytokine correlates of diagnostic tests for latent tuberculous infection in HIV-1-infected subjects.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2015
Same author

Inhibition of Mycobacterium tuberculosis-induced signalling by transforming growth factor-β in human mononuclear phagocytes.

Scandinavian journal of immunology·2011
Same author

Polyfunctional Mycobacterium tuberculosis-specific effector memory CD4+ T cells at sites of pleural TB.

Tuberculosis (Edinburgh, Scotland)·2011
Same author

Distinct cytokine and regulatory T cell profile at pleural sites of dual HIV/tuberculosis infection compared to that in the systemic circulation.

Clinical and experimental immunology·2011
Same author

Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection.

The European respiratory journal·2009
Same author

The interaction of monocyte chemoattractant protein-1 and tumour necrosis factor-alpha in Mycobacterium tuberculosis-induced HIV-1 replication at sites of active tuberculosis.

Scandinavian journal of immunology·2009

Adjunctive immunotherapy offers a promising approach to combat tuberculosis (TB) by enhancing the host immune response against Mycobacterium tuberculosis. This strategy may overcome limitations of current chemotherapy, especially for difficult-to-treat cases.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Medical Microbiology

Background:

  • Tuberculosis (TB) remains a significant global health challenge, causing substantial morbidity and mortality.
  • Current antitubercular chemotherapy faces challenges including patient compliance, drug toxicity, and incomplete eradication of Mycobacterium tuberculosis.
  • Understanding the immunopathogenesis of TB opens avenues for novel therapeutic strategies.

Purpose of the Study:

  • To explore the potential of adjunctive immunotherapy in improving tuberculosis treatment outcomes.
  • To identify host immune responses and cytokine modulations that could enhance antimycobacterial immunity.
  • To evaluate the utility of immunotherapy for challenging TB cases and in immunocompromised individuals.

Main Methods:

Related Experiment Videos

  • Review of current understanding of tuberculosis immunopathogenesis.
  • Analysis of potential immunotherapeutic targets, including T helper 1 cytokines (interferon-gamma, IL-2, IL-12) and inhibitory cytokines (transforming growth factor-beta).
  • Consideration of local administration and combination therapies to modulate the granuloma cytokine environment.

    • Main Results:

    • Upregulating T helper 1 cytokines can enhance T-cell function and macrophage activation, boosting antimycobacterial responses.
    • Inhibiting suppressive cytokines like transforming growth factor-beta and reducing pro-inflammatory molecules may be beneficial.
    • Targeting the local cytokine milieu within granulomas is a key consideration for effective immunotherapy.

    Conclusions:

    • Adjunctive immunotherapy holds promise for enhancing the efficacy of tuberculosis treatment.
    • Modulating the host immune response, particularly through cytokine manipulation, is a viable therapeutic strategy.
    • Immunotherapy may be particularly valuable for drug-resistant TB, disseminated disease, and in immunocompromised patients.